Drug interactions
Liposomal doxorubicin + Voxelotor
Severity: Moderate
Liposomal doxorubicin and Voxelotor: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Voxelotor inhibits CYP3A4 and may raise exposure to CYP3A4 substrates. Doxorubicin is metabolised only partly by CYP3A4, and the liposomal form has distinct pharmacokinetics, so the clinical effect is uncertain but could increase anthracycline toxicity such as myelosuppression and cardiotoxicity.
What this interaction means in plain words
Liposomal doxorubicin and Voxelotor can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Liposomal doxorubicin belongs to Oncology; Voxelotor belongs to Miscellaneous.
Why it happens
Voxelotor inhibits CYP3A4, potentially reducing the metabolism of doxorubicin.
What to do
Monitor blood counts and cardiac function more closely when the combination is needed. Consider a doxorubicin dose reduction if signs of toxicity appear.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Liposomal doxorubicin and Voxelotor, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Liposomal doxorubicin
- Dengue vaccine + Liposomal doxorubicin Contraindicated
- Belatacept + Liposomal doxorubicin Major
- Cyclosporine + Liposomal doxorubicin Major
- Dronedarone + Liposomal doxorubicin Major
- Elvitegravir / cobicistat / emtricitabine / tenofovir df + Liposomal doxorubicin Major
- Fingolimod + Liposomal doxorubicin Major
Other interactions of Voxelotor
- Amobarbital + Voxelotor Major
- Apalutamide + Voxelotor Major
- Carbamazepine + Voxelotor Major
- Cyclosporin + Voxelotor Major
- Efavirenz + Voxelotor Major
- Enzalutamide + Voxelotor Major
Frequently asked questions
Can I take Liposomal doxorubicin with Voxelotor?
MediHelp rates the interaction as moderate. Liposomal doxorubicin and Voxelotor can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Voxelotor inhibits CYP3A4 and may raise exposure to CYP3A4 substrates. Doxorubicin is metabolised only partly by CYP3A4, and the liposomal form has distinct pharmacokinetics, so the clinical effect is uncertain but could increase anthracycline toxicity such as myelosuppression and cardiotoxicity.
How serious is the interaction between Liposomal doxorubicin and Voxelotor?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood counts and cardiac function more closely when the combination is needed. Consider a doxorubicin dose reduction if signs of toxicity appear.
What other medicines interact with Liposomal doxorubicin?
MediHelp also lists interactions of Liposomal doxorubicin with, for example, Dengue vaccine, Belatacept, Cyclosporine. The full list is on the Liposomal doxorubicin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
